Marantic endocarditis is a condition in which sterile clumps of fibrin and platelets form on heart valves without any bacterial infection being present. The medical literature more often calls it nonbacterial thrombotic endocarditis (NBTE), and it is most closely linked to advanced cancer and certain autoimmune diseases. Despite being found at autopsy roughly three times more often than infectious endocarditis, it is frequently missed during life because it rarely produces the classic signs clinicians are trained to look for in valve disease.
What Forms on the Valves and Why
The growths, called vegetations, range from microscopic platelet clumps to large, visible masses attached to valve leaflets that were previously undamaged. They sit along the closure line of the valve and are made mostly of fibrin and platelets with very little inflammation mixed in. That composition matters: because the vegetations lack the organized, adherent structure of an infected mass, they are fragile and prone to breaking off and traveling through the bloodstream. The aortic and mitral valves are affected most often.
The process starts when something shifts the blood into a strongly clot-prone state. In cancer patients, tumors release substances that activate clotting, including tissue factor and a protein called cancer procoagulant. Inflammatory signaling molecules and, in some mucin-producing cancers, circulating mucin itself contribute to platelet and fibrin deposits on otherwise intact valve surfaces. Early work on mucin-producing adenocarcinomas showed that histochemically stainable mucin was an integral part of both the valve vegetations and distant blood clots, and that circulating mucin appeared in the blood before the vegetations developed, pointing to a direct role for tumor mucin in triggering the condition.
Cancer and Autoimmune Connections
Cancer is the single most common underlying cause. Pancreatic, lung, and other mucin-secreting adenocarcinomas carry a particularly strong association, but marantic endocarditis has been reported across a wide range of solid tumors. The prothrombotic environment created by advanced malignancy, sometimes called Trousseau syndrome, sets the stage for valve deposits as one of many possible clotting complications. One autopsy-based estimate puts the prevalence of NBTE at about 3.7% in general autopsy series, but in high-risk groups such as cancer patients or those with autoimmune conditions, rates can reach roughly 15%.
The other major category is autoimmune disease, especially systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). In these conditions, antiphospholipid antibodies appear to promote thrombus formation on valves through at least two pathways. The antibodies may directly encourage clot deposition, and researchers have also found subendothelial deposits of immunoglobulins, including anticardiolipin antibodies, along with complement components in deformed valves from APS patients, suggesting the antibodies themselves may damage valve tissue. When marantic endocarditis occurs in the setting of lupus, it is sometimes called Libman-Sacks endocarditis, though that term historically covers a somewhat broader spectrum of lupus-related valve disease.
A nationwide study of SLE patients hospitalized with marantic endocarditis in the United States found that antiphospholipid syndrome, stroke, female sex, younger age, anemia, and acute kidney injury were all independently associated with higher inpatient mortality. Antiphospholipid syndrome and stroke carried the strongest associations with death during hospitalization.
How It Shows Up Clinically
The tricky part about marantic endocarditis is that it often does not announce itself through the heart. Unlike infectious endocarditis, which typically produces fever, a new heart murmur, and positive blood cultures, NBTE tends to stay silent on the cardiac side until a piece of vegetation breaks off and lodges somewhere downstream. A heart murmur is found in fewer than half of cases. Blood cultures come back negative because there is no infection.
The most common way patients come to attention is through an embolic event. A systematic review and meta-analysis covering 416 reported cases found that stroke-like symptoms were the single most frequent presentation, and embolic complications occurred in about 70% of cases, most of them strokes. The emboli can also travel to the spleen, kidneys, extremities, and coronary arteries, producing organ damage that may initially be mistaken for other causes. Cancer patients had substantially higher odds of embolic complications compared to patients with other underlying causes of NBTE.
This pattern creates a diagnostic trap: a patient with known cancer or lupus who develops a stroke or peripheral embolism may undergo extensive workup for other explanations before anyone considers vegetations sitting silently on a heart valve. The condition should be on the radar whenever a patient with a known prothrombotic illness develops unexplained emboli, especially if those emboli hit multiple vascular territories at once.
Telling It Apart from Infective Endocarditis
Because both marantic and infectious endocarditis can produce vegetations on echocardiography and, occasionally, fever, distinguishing them matters enormously for treatment. Infectious endocarditis is treated with weeks of antibiotics, sometimes with surgery; NBTE is treated with anticoagulation and management of the underlying disease. Giving antibiotics alone to a patient with NBTE wastes time and does nothing to prevent the next embolism.
The hallmark of infectious endocarditis is sustained bacteremia: repeatedly positive blood cultures with an organism known to infect heart valves. Once the recognized causes of culture-negative infectious endocarditis have been excluded, the absence of bacteremia is what separates marantic endocarditis from its infectious counterpart. Leukocytosis and a markedly elevated sedimentation rate lean toward infection, while a hypercoagulable state with negative cultures in a patient who has cancer or an autoimmune condition leans toward NBTE. In practice, though, the two can look frustratingly similar on initial workup, and clinicians sometimes start empiric antibiotics while sorting it out.
Imaging and the Echocardiography Gap
Standard transthoracic echocardiography (TTE), the bedside ultrasound of the heart that most patients get first, catches NBTE vegetations less than half the time. In a 20-year Cleveland Clinic series of 42 patients with confirmed NBTE, TTE identified the vegetations in only about 45% of cases, while transesophageal echocardiography (TEE), which places the ultrasound probe in the esophagus directly behind the heart, detected them in 97% of cases where it was used. The reason is straightforward: NBTE vegetations are often small, sometimes under 5 mm, and sit in locations that TTE images poorly.
This gap has a practical consequence. In a patient with a high clinical suspicion of NBTE, such as someone with multi-territory strokes in the setting of cancer or autoimmune disease, a negative TTE should not end the search. A follow-up TEE is considered essential to properly assess for vegetations. Missing the diagnosis means the patient stays on whatever anticoagulation regimen they happen to be on, which may not be the right one, and the underlying valve problem continues to shed emboli.
Beyond echocardiography, cardiac CT and cardiac MRI are gaining recognition as complementary tools. CT offers the highest spatial resolution among cardiac imaging modalities and can simultaneously look for vegetations, peripheral and cerebral emboli, and underlying malignancies in a single full-body scan. Cardiac MRI can detect and characterize vegetations, identify endocardial inflammation even when no obvious mass is visible, and assess cerebral emboli in the same session. Neither has replaced TEE as the go-to confirmatory test, but both are useful when the clinical picture is ambiguous or when additional information about embolization is needed.
Why Anticoagulation Is Not One-Size-Fits-All
Preventing further embolism is the central goal once marantic endocarditis is diagnosed, and that means anticoagulation. But which anticoagulant to use has been a contentious and evolving question. For decades, unfractionated heparin and low-molecular-weight heparin (LMWH) have been regarded as the most reliable options in cancer-associated NBTE, and the clinical literature broadly supports that view. A systematic review of cancer-associated NBTE found that switching patients from direct oral anticoagulants (DOACs) to heparin-based therapy led to better outcomes in terms of vegetation resolution and prevention of further embolic events. Case reports have described patients who suffered recurrent strokes despite being on DOACs, only to stabilize after transitioning to heparin.
The picture is not entirely settled, however. A larger database analysis found no statistically significant difference in thromboembolic events or mortality among patients treated with heparin or LMWH, DOACs, or warfarin. Patients on heparin or LMWH did have significantly longer hospital stays compared with those on DOACs or warfarin. The authors suggested that DOACs and warfarin may be reasonable alternatives, particularly when long-term subcutaneous heparin injections are impractical or when the patient’s quality of life is a major consideration.
This tension reflects a broader reality: there are no large randomized trials comparing anticoagulant strategies head-to-head in NBTE, and there probably never will be, given how uncommon the diagnosis is in clinical practice. Most of the evidence comes from case series, case reports, and retrospective database studies. Clinicians tend to start with heparin-based therapy in the acute setting, especially if there has been a recent embolism, and then decide case by case whether to continue with LMWH or transition to an oral agent for longer-term management. The decision often depends on the underlying disease, the patient’s tolerance for injections, and whether there is an active malignancy that could interact with oral anticoagulants.
When Surgery Enters the Picture
Most patients with marantic endocarditis are managed medically, but surgery becomes a consideration when anticoagulation alone is failing. Formal surgical indications have not been studied in dedicated trials, and guidelines generally follow those used for infectious endocarditis: uncontrollable heart failure, persistent emboli despite adequate anticoagulation, or large mobile vegetations judged to pose a high embolic risk. Because the vegetations in NBTE sit on structurally normal valve tissue, valve repair rather than replacement is sometimes possible once the vegetation is removed, which is less often the case in infectious endocarditis where the valve itself is damaged by bacteria.
The challenge is that many NBTE patients are seriously ill from their underlying disease. A patient with metastatic cancer may not tolerate open-heart surgery. The decision to operate involves weighing the immediate embolic risk against surgical risk and remaining life expectancy. When patients are stable enough for surgery and meet standard valve surgery indications, reports describe successful outcomes, including cases of mitral valve replacement that produced good short-term results. Still, surgery in this population is uncommon, and most clinicians treat it as a last resort reserved for patients whose embolic burden is clearly going to be fatal without intervention.
Prognosis and What Drives It
The prognosis of marantic endocarditis depends heavily on what is causing it. In patients with advanced, untreatable cancer, the outlook is grim regardless of how effectively the vegetations are managed, because the underlying malignancy is driving the prothrombotic state and will continue to do so. Embolic strokes in this setting add devastating neurological injury on top of an already terminal illness.
In autoimmune-related NBTE, the prognosis can be better if the underlying disease is controlled. Effective treatment of lupus or antiphospholipid syndrome can reduce the prothrombotic drive that feeds vegetations, and long-term anticoagulation can keep emboli at bay. However, even in this group, complications pile up quickly. The nationwide study of SLE patients with NBTE found that stroke complicating the condition was one of the strongest predictors of inpatient death, with adjusted odds nearly tenfold higher than in patients without stroke. Anemia and kidney injury further worsened the odds.
Because the condition is so tightly linked to embolic events, early diagnosis and prompt anticoagulation are the most impactful interventions available. Every day that vegetations sit unrecognized on a valve is another day a fragment could break off and cause a stroke or organ infarction. This is why the imaging gap between TTE and TEE described earlier is not just an academic observation but a practical problem with direct consequences for patients.
The Search for Better Diagnostic Tools
One of the frustrations with marantic endocarditis is that no blood test can reliably confirm it. The diagnosis depends on imaging findings in the right clinical context, and as outlined above, the most accessible form of cardiac imaging misses roughly half of cases. Researchers have pointed out that a biomarker capable of distinguishing NBTE from infective endocarditis would have major clinical value. Candidate tests under discussion include clotting-time assays, lupus anticoagulant testing, solid-phase antiphospholipid antibody panels, autoantibody screens for connective tissue diseases, and tumor markers. None has been validated as a standalone diagnostic marker for NBTE, but the idea is that a panel of such tests, combined with negative blood cultures and the right clinical setting, could prompt earlier TEE and faster diagnosis.
D-dimer, a nonspecific marker of clot formation and breakdown, is almost always elevated in NBTE patients but is also elevated in cancer, infection, surgery, and dozens of other situations, making it useless as a specific test. Its main value is negative: a normal D-dimer in a patient with suspected NBTE makes the diagnosis less likely. Beyond that, the field is still waiting for something better. Until a validated biomarker panel arrives, the clinical approach remains pattern recognition: unexplained emboli plus a prothrombotic underlying disease plus negative blood cultures should trigger a TEE, even if the TTE looks normal.
Why the Name Persists
The term “marantic” comes from the Greek word marasmos, meaning wasting or withering. It dates to an era when the condition was most often discovered at autopsy in patients who had died of debilitating chronic illnesses, and the vegetations were thought to be a byproduct of the body’s general decline. The name is somewhat misleading by modern standards because we now understand that the vegetations are not simply a marker of wasting but an active clotting process driven by specific procoagulant mechanisms. “Nonbacterial thrombotic endocarditis” is the preferred term in current medical literature because it more accurately describes what is happening: thrombosis on the endocardium without bacterial involvement. Still, “marantic endocarditis” persists in clinical shorthand and in case reports, partly out of tradition and partly because it distinguishes the condition from Libman-Sacks endocarditis in conversation, even though the two overlap in autoimmune patients. If you see either term in a medical record or a pathology report, they are referring to the same fundamental process.